{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:27:31Z","timestamp":1791430051921,"version":"4.3.3"},"reference-count":345,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Programa Grupos de Investigaci\u00f3n, CSIC, Universidad de la Rep\u00fablica, Uruguay","award":["number 908"],"award-info":[{"award-number":["number 908"]}]},{"name":"Fondo para la Convergencia Estructural del MERCOSUR","award":["COF 03\/11"],"award-info":[{"award-number":["COF 03\/11"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Aberrant glycosylation is a hallmark of cancer and can lead to changes that influence tumor behavior. Glycans can serve as a source of novel clinical biomarker developments, providing a set of specific targets for therapeutic intervention. Different mechanisms of aberrant glycosylation lead to the formation of tumor-associated carbohydrate antigens (TACAs) suitable for selective cancer-targeting therapy. The best characterized TACAs are truncated O-glycans (Tn, TF, and sialyl-Tn antigens), gangliosides (GD2, GD3, GM2, GM3, fucosyl-GM1), globo-serie glycans (Globo-H, SSEA-3, SSEA-4), Lewis antigens, and polysialic acid. In this review, we analyze strategies for cancer immunotherapy targeting TACAs, including different antibody developments, the production of vaccines, and the generation of CAR-T cells. Some approaches have been approved for clinical use, such as anti-GD2 antibodies. Moreover, in terms of the antitumor mechanisms against different TACAs, we show results of selected clinical trials, considering the horizons that have opened up as a result of recent developments in technologies used for cancer control.<\/jats:p>","DOI":"10.3390\/cancers14030645","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T21:59:55Z","timestamp":1643320795000},"page":"645","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-2540","authenticated-orcid":false,"given":"Nora","family":"Berois","sequence":"first","affiliation":[{"name":"Laboratorio de Glicobiolog\u00eda e Inmunolog\u00eda Tumoral, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Pittini","sequence":"additional","affiliation":[{"name":"Laboratorio de Glicobiolog\u00eda e Inmunolog\u00eda Tumoral, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay"},{"name":"Departamento de Inmunobiolog\u00eda, Facultad de Medicina, Universidad de la Rep\u00fablica, Montevideo 11800, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Osinaga","sequence":"additional","affiliation":[{"name":"Laboratorio de Glicobiolog\u00eda e Inmunolog\u00eda Tumoral, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay"},{"name":"Departamento de Inmunobiolog\u00eda, Facultad de Medicina, Universidad de la Rep\u00fablica, Montevideo 11800, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1038\/s41467-020-17140-5","article-title":"Cancer immunotherapy comes of age and looks for maturity","volume":"11","author":"Finck","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1038\/s41388-021-01811-8","article-title":"Antibody-based cancer therapy","volume":"40","author":"Goydel","year":"2021","journal-title":"Oncogene"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.cell.2006.08.019","article-title":"Glycosylation in cellular mechanisms of health and disease","volume":"126","author":"Ohtsubo","year":"2006","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc3982","article-title":"Glycosylation in cancer: Mechanisms and clinical implications","volume":"15","author":"Pinho","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/cbic.201600705","article-title":"Gangliosides: Structures, Biosynthesis, Analysis, and Roles in Cancer","volume":"18","author":"Delannoy","year":"2017","journal-title":"ChemBioChem"},{"key":"ref_8","first-page":"188464","article-title":"Biochim Biophys Altered glycosylation in cancer: A promising target for biomarkers and therapeutics","volume":"1875","author":"Thomas","year":"2021","journal-title":"Acta Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1093\/glycob\/cwu083","article-title":"Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment","volume":"24","author":"Croci","year":"2014","journal-title":"Glycobiology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ccell.2019.06.006","article-title":"Glycosylation in the Era of Cancer-Targeted Therapy: Where Are We Heading?","volume":"36","author":"Mereiter","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1073\/pnas.1907921117","article-title":"Glioblastomas exploit truncated O-linked glycans for local and distant immune modulation via the macrophage galactose-type lectin","volume":"117","author":"Dusoswa","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/nrc1649","article-title":"The sweet and sour of cancer: Glycans as novel therapeutic targets","volume":"5","author":"Fuster","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e1061177","DOI":"10.1080\/2162402X.2015.1061177","article-title":"Cancer cell associated glycans as targets for immunotherapy","volume":"5","author":"Vankemmelbeke","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nri.2018.3","article-title":"The tumour glyco-code as a novel immune checkpoint for immunotherapy","volume":"18","author":"Schetters","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1111\/febs.15830","article-title":"Emerging glyco-based strategies to steer immune responses","volume":"288","author":"Anderluh","year":"2021","journal-title":"FEBS J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1074-5521(97)90253-2","article-title":"Glycosphingolipid antigens and cancer therapy","volume":"4","author":"Hakomori","year":"1997","journal-title":"Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s10529-019-02675-5","article-title":"Recent advances in carbohydrate-based cancer vaccines","volume":"41","author":"Jin","year":"2019","journal-title":"Biotechnol. Lett."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.4049\/jimmunol.174.9.5706","article-title":"Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity","volume":"174","author":"Ragupathi","year":"2005","journal-title":"J. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1158\/0008-5472.CAN-10-4222","article-title":"Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy","volume":"71","author":"Hubert","year":"2011","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-015-0399-5","article-title":"Dinutuximab: First global approval","volume":"75","author":"Dhillon","year":"2015","journal-title":"Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.bbagen.2007.08.015","article-title":"Structure and function of glycosphingolipids and sphingolipids: Recollections and future trends","volume":"1780","author":"Hakomori","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1111\/febs.12559","article-title":"Glycosphingolipids: Synthesis and functions","volume":"280","author":"Capasso","year":"2013","journal-title":"FEBS J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.febslet.2009.10.065","article-title":"Glycosynaptic microdomains controlling tumor cell phenotype through alteration of cell growth, adhesion, and motility","volume":"584","author":"Hakomori","year":"2010","journal-title":"FEBS Lett."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1002\/1873-3468.13917","article-title":"Targeting glycosphingolipids for cancer immunotherapy","volume":"594","author":"Yu","year":"2020","journal-title":"FEBS Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1089\/scd.2016.0138","article-title":"Alterations of Glycosphingolipids in Embryonic Stem Cell Differentiation and Development of Glycan-Targeting Cancer Immunotherapy","volume":"25","author":"Yu","year":"2016","journal-title":"Stem Cells Dev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.bbagen.2007.10.008","article-title":"Functional role of glycosphingolipids and gangliosides in control of cell adhesion, motility, and growth, through glycosynaptic microdomains","volume":"1780","author":"Hakomori","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cumin, C., Huang, Y.L., Everest-Dass, A., and Jacob, F. (2021). Deciphering the Importance of Glycosphingolipids on Cellular and Molecular Mechanisms Associated with Epithelial-to-Mesenchymal Transition in Cancer. Biomolecules, 11.","DOI":"10.3390\/biom11010062"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.3390\/ijms15034356","article-title":"Sphingolipids: Key regulators of apoptosis and pivotal players in cancer drug resistance","volume":"15","author":"Giussani","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0022-510X(97)05390-2","article-title":"Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy","volume":"149","author":"Yuki","year":"1997","journal-title":"J. Neurol. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cavdarli, S., Groux-Degroote, S., and Delannoy, P. (2019). Gangliosides: The Double-Edge Sword of Neuro-Ectodermal Derived Tumors. Biomolecules, 9.","DOI":"10.3390\/biom9080311"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1349-7006.2002.tb01324.x","article-title":"An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation","volume":"93","author":"Yoshida","year":"2002","journal-title":"Jpn. J. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Doronin, I.I., Vishnyakova, P.A., Kholodenko, I.V., Ponomarev, E.D., Ryazantsev, D.Y., Molotkovskaya, I.M., and Kholodenko, R.V. (2014). Ganglioside GD2 in reception and transduction of cell death signal in tumor cells. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-295"},{"key":"ref_35","first-page":"363","article-title":"Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function","volume":"61","author":"Shurin","year":"2001","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1007\/s00262-012-1286-5","article-title":"Phase II trial of hu14.18-IL2 for patients with metastatic melanoma","volume":"61","author":"Albertini","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4161\/onci.19864","article-title":"Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo","volume":"1","author":"Cheung","year":"2012","journal-title":"Oncoimmunology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2011.41.3807","article-title":"Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission","volume":"30","author":"Cheung","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.4049\/jimmunol.144.4.1382","article-title":"Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody","volume":"144","author":"Mueller","year":"1990","journal-title":"J. Immunol."},{"key":"ref_41","first-page":"144","article-title":"Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells","volume":"51","author":"Barker","year":"1991","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.semcancer.2011.09.012","article-title":"Immunology and immunotherapy of neuroblastoma","volume":"21","author":"Seeger","year":"2011","journal-title":"Semin. Cancer Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jamaoncol.2018.4005","article-title":"Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing with Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Resistant Neuroblastoma: A Phase 1 Clinical Trial","volume":"4","author":"Kushner","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1358331","DOI":"10.1080\/2162402X.2017.1358331","article-title":"Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival","volume":"6","author":"Cheung","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/14728214.2019.1654455","article-title":". An update on emerging drugs in osteosarcoma: Towards tailored therapies?","volume":"24","author":"Hattinger","year":"2019","journal-title":"Expert. Opin. Emerg. Drugs"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-018-2223-z","article-title":"Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma","volume":"67","author":"Albertini","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1158\/1078-0432.CCR-19-3294","article-title":"Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III\/IV Melanoma Evaluated after Starting Hu14.18-IL2","volume":"26","author":"Yang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.19.01410","article-title":"Targets and Antibody Formats for Immunotherapy of Neuroblastoma","volume":"38","author":"Park","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_49","first-page":"561","article-title":"A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma","volume":"21","author":"Forero","year":"2006","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000353","article-title":"Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-\u03b12b in patients with metastatic melanoma","volume":"27","author":"Tarhini","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.jtho.2021.01.085","article-title":"Clinical Activity of BMS-986012, an AntieFucosyl-GM1 Monoclonal Antibody, Plus Nivolumab in Small Cell Lung Cancer","volume":"16","author":"Chu","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejca.2016.05.003","article-title":"A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas","volume":"63","author":"Fiedler","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"v626","DOI":"10.1093\/annonc\/mdx440.035","article-title":"LBA41A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma","volume":"28","author":"Ledermann","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1200\/JCO.2021.39.15_suppl.2522","article-title":"Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors","volume":"39","author":"Garralda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","first-page":"381","article-title":"Radioimmunoscintigraphy in patients with breast adenocarcinoma using technetium-99m labelled monoclonal antibody 170H.82: Report of a phase II study","volume":"24","author":"McQuarrie","year":"1997","journal-title":"Eur J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"231","DOI":"10.21037\/jgo.2020.02.01","article-title":"Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer","volume":"11","author":"Gupta","year":"2020","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e3181560dcc","article-title":"Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: A pilot trial testing two dose levels","volume":"2","author":"Krug","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ygyno.2015.05.023","article-title":"A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant\/refractory ovarian, fallopian tube and primary peritoneal carcinoma","volume":"138","author":"Smaletz","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.lungcan.2006.05.020","article-title":"A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma","volume":"54","author":"Ross","year":"2006","journal-title":"Lung Cancer."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.copbio.2019.11.020","article-title":"Bispecific antibodies in cancer immunotherapy","volume":"65","author":"Rader","year":"2020","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.smim.2020.101390","article-title":"Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy","volume":"47","author":"Rashidijahanabad","year":"2020","journal-title":"Semin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0959-8049(95)00013-9","article-title":"In vivo targeting of human neuroblastoma xenograft by anti-GD2\/anti-Fc gamma RI (CD64) bispecific antibody","volume":"31A","author":"Michon","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/ijc.29007","article-title":"Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy","volume":"136","author":"Cheng","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e1168557","DOI":"10.1080\/2162402X.2016.1168557","article-title":"Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors","volume":"5","author":"Cheng","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1158\/2326-6066.CIR-14-0230-T","article-title":"Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody","volume":"3","author":"Xu","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e002923","DOI":"10.1136\/jitc-2021-002923","article-title":"GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma","volume":"9","author":"Zirngibl","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/1078-0432.CCR-13-1012","article-title":"Phase I trial of a bivalent gangliosides vaccine in combination with \u03b2-glucan for high-risk neuroblastoma in second or later remission","volume":"20","author":"Kushner","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1200\/JCO.20.01892","article-title":"Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression","volume":"39","author":"Cheung","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_69","first-page":"1319","article-title":"Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Grant","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6854","DOI":"10.1200\/JCO.2005.17.186","article-title":"Phase III study of adjuvant vaccination with Bec2\/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study)","volume":"23","author":"Giaccone","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.ejca.2008.06.036","article-title":"Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2\/BCG in responding patients with limited disease small-cell lung cancer","volume":"44","author":"Bottomley","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/pbc.25631","article-title":"A Phase I Study of the Anti-Idiotype Vaccine Racotumomab in Neuroblastoma and Other Pediatric Refractory Malignancies","volume":"62","author":"Cacciavillano","year":"2015","journal-title":"Pediatr. Blood Cancer."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e000342","DOI":"10.1136\/jitc-2019-000342","article-title":"Globo H-KLH vaccine adagloxad simolenin (OBI-822)\/OBI-821 in patients with metastatic breast cancer: Phase II randomized, placebo-controlled study","volume":"8","author":"Huang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00262-020-02503-0","article-title":"The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients","volume":"69","author":"Rosenbaum","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7150\/jca.7028","article-title":"Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial","volume":"4","author":"Ibrahim","year":"2013","journal-title":"J. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1007\/s00262-004-0598-5","article-title":"Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: Clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer","volume":"54","author":"Slovin","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1200\/jco.2011.29.15_suppl.2599","article-title":"A pilot study of vaccination with sialyl Lewisa (sLea)\u2013keyhole limpet hemocyanin (KLH) conjugate plus the immunologic adjuvant QS-21 in metastatic breast cancer patients (pts)","volume":"29","author":"Diab","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00262-011-1083-6","article-title":"Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci","volume":"61","author":"Krug","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"O'Cearbhaill, R.E., Ragupathi, G., Zhu, J., Wan, Q., Mironov, S., Yang, G., Spassova, M.K., Iasonos, A., Kravetz, S., and Ouerfelli, O. (2016). A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission. Cancers, 8.","DOI":"10.3390\/cancers8040046"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"572965","DOI":"10.3389\/fnins.2020.572965","article-title":"Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications","volume":"14","author":"Sipione","year":"2020","journal-title":"Front. Neurosci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1020211714104","article-title":"Gangliosides with O-acetylated sialic acids in tumors of neuroectodermal origin","volume":"27","author":"Kohla","year":"2002","journal-title":"Neurochem. Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Pruszak, J. (2015). Glycolipid Antigens in Neural Stem Cells. Neural Surface Antigens, Academic Press.","DOI":"10.1016\/B978-0-12-800781-5.05001-5"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1073\/pnas.1604721113","article-title":"Glycolipid GD3 and GD3 synthase are key drivers for glioblastoma stem cells and tumorigenicity","volume":"113","author":"Yeh","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.apsb.2018.07.009","article-title":"Ganglioside GD3 synthase (GD3S), a novel cancer drug target","volume":"8","author":"Liu","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_86","first-page":"308","article-title":"Common phenotypic expression of gangliosides GM3 and GD3 in normal human tissues and neoplastic skin lesions","volume":"22","author":"Nakakuma","year":"1992","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"27213","DOI":"10.1074\/jbc.M109.087791","article-title":"Ganglioside GD3 enhances adhesion signals and augments malignant properties of melanoma cells by recruiting integrins to glycolipid-enriched microdomains","volume":"285","author":"Ohkawa","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/1878-0261.12702","article-title":"Upregulation of cell surface GD3 ganglioside phenotype is associated with human melanoma brain metastasis","volume":"14","author":"Ramos","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.1073\/pnas.77.10.6114","article-title":"Cell surface antigens of human malignant melanoma: Definition of six antigenic systems with mouse monoclonal antibodies","volume":"77","author":"Dippold","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1073\/pnas.82.5.1499","article-title":"Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside","volume":"82","author":"Brankovan","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/BF01740908","article-title":"Antitumor effects of a novel monoclonal antibody with high binding affinity to ganglioside GD3","volume":"36","author":"Ohta","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_92","first-page":"4401","article-title":"Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: Specificity analysis and comparison of antigen expression in cultured cells and tissues","volume":"45","author":"Real","year":"1985","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1097\/00008390-199708001-00024","article-title":"Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside","volume":"7","author":"Nasi","year":"1997","journal-title":"Melanoma Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/BF01533387","article-title":"Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody","volume":"39","author":"Chapman","year":"1994","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1200\/JCO.2001.19.19.3976","article-title":"Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: Results of a phase I trial","volume":"19","author":"Scott","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1172\/JCI115276","article-title":"Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody","volume":"88","author":"Chapman","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_97","first-page":"679","article-title":"Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: Enhanced immunogenicity when combined with adjuvant","volume":"2","author":"McCaffery","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"ref_98","first-page":"1300","article-title":"Immunohistological detection of fucosyl-GM1 ganglioside in human lung cancer and normal tissues with monoclonal antibodies","volume":"49","author":"Brezicka","year":"1989","journal-title":"Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<42::AID-IJC8>3.0.CO;2-1","article-title":"Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides","volume":"73","author":"Zhang","year":"1997","journal-title":"Int. J. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Groux-Degroote, S., and Delannoy, P. (2021). Cancer-Associated Glycosphingolipids as Tumor Markers and Targets for Cancer Immunotherapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116145"},{"key":"ref_101","first-page":"2773","article-title":"Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer","volume":"5","author":"Dickler","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-04-0482","article-title":"Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin","volume":"10","author":"Krug","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ijc.2910490619","article-title":"Tumor-cell killing by MAbs against fucosyl GM1, a ganglioside antigen associated with small-cell lung carcinoma","volume":"49","author":"Brezicka","year":"1991","journal-title":"Int. J. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s002620000096","article-title":"Functional assessment in vitro of human-complement-dependent antibody-induced cytotoxicity of neoplastic cells","volume":"49","author":"Brezicka","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.1158\/1078-0432.CCR-18-0018","article-title":"A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer","volume":"24","author":"Ponath","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jnci\/78.1.45","article-title":"Gangliosides of human melanoma","volume":"78","author":"Tsuchida","year":"1987","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2174\/0929867325666180129100619","article-title":"Ganglioside GM3 and Its Role in Cancer","volume":"26","author":"Zheng","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/bcr1841","article-title":"Silencing of GM3 synthase suppresses lung metastasis of murine breast cancer cells","volume":"10","author":"Gu","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Tringali, C., Silvestri, I., Testa, F., Baldassari, P., Anastasia, L., Mortarini, R., Anichini, A., L\u00f3pez-Requena, A., Tettamanti, G., and Venerando, B. (2014). Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-560"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"13328","DOI":"10.1016\/S0021-9258(17)38873-7","article-title":"Syngeneic monoclonal antibody against melanoma antigen with interspecies cross-reactivity recognizes GM3, a prominent ganglioside of B16 melanoma","volume":"260","author":"Hirabayashi","year":"1985","journal-title":"J. Biol. Chem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.4049\/jimmunol.139.9.3171","article-title":"Density-dependent recognition of cell surface GM3 by a certain anti-melanoma antibody, and GM3 lactone as a possible immunogen: Requirements for tumor-associated antigen and immunogen","volume":"139","author":"Nores","year":"1987","journal-title":"J. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1158\/0008-5472.CAN-09-1099","article-title":"De-N-acetyl GM3 promotes melanoma cell migration and invasion through urokinase plasminogen activator receptor signaling-dependent MMP-2 activation","volume":"69","author":"Liu","year":"2009","journal-title":"Cancer Res."},{"key":"ref_113","first-page":"814397","article-title":"NGcGM3 ganglioside: A privileged target for cancer vaccines","volume":"2010","author":"Fernandez","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"15866","DOI":"10.1074\/jbc.273.25.15866","article-title":"The molecular basis for the absence of N-glycolylneuraminic acid in humans","volume":"273","author":"Irie","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"02417","DOI":"10.1155\/2013\/602417","article-title":"Tissue Reactivity of the 14F7 Mab Raised against N-Glycolyl GM3 Ganglioside in Tumors of Neuroectodermal, Mesodermal, and Epithelial Origin","volume":"2013","author":"Blanco","year":"2013","journal-title":"J. Biomark."},{"key":"ref_116","first-page":"33","article-title":"Involvement of a non-human sialic Acid in human cancer","volume":"4","author":"Samraj","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-005-9064-0","article-title":"Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc","volume":"96","author":"Oliva","year":"2006","journal-title":"Breast Cancer Res Treat."},{"key":"ref_118","first-page":"132326","article-title":"Prognostic Significance of N-Glycolyl GM3 Ganglioside Expression in Non-Small Cell Lung Carcinoma Patients: New Evidences","volume":"2015","author":"Blanco","year":"2015","journal-title":"Patholog. Res. Int."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminoncol.2018.04.003","article-title":"GM3(Neu5Gc) ganglioside: An evolution fixed neoantigen for cancer immunotherapy","volume":"45","author":"Labrada","year":"2018","journal-title":"Semin. Oncol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/02724570050109639","article-title":"A mouse IgG1 monoclonal antibody specific for N-glycolyl GM3 ganglioside recognized breast and melanoma tumors","volume":"19","author":"Carr","year":"2000","journal-title":"Hybridoma"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.imbio.2011.07.004","article-title":"A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates","volume":"216","author":"Dorvignit","year":"2011","journal-title":"Immunobiology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.imbio.2015.07.008","article-title":"Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside","volume":"220","author":"Dorvignit","year":"2015","journal-title":"Immunobiology"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"9921","DOI":"10.1038\/s41598-019-46148-1","article-title":"Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells","volume":"9","author":"Dorvignit","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0264-410X(99)00219-4","article-title":"Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP)","volume":"18","author":"Estevez","year":"1999","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2147\/CMAR.S22617","article-title":"Effect of vaccination with N-glycolyl GM3\/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma","volume":"4","author":"Osorio","year":"2012","journal-title":"Cancer Manag. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1200\/JCO.2003.02.124","article-title":"del C.; Camacho, R.; Osorio, M.; Gabri, M.; Carrillo, G.; Vald\u00e9s, Z.; Bebelagua, Y.; P\u00e9rez, R.; et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine","volume":"21","author":"Carr","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"736","DOI":"10.4161\/hv.6.9.12571","article-title":"Immunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients","volume":"6","author":"Mulens","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.4161\/hv.24115","article-title":"NGcGM3\/VSSP vaccine as treatment for melanoma patients","volume":"9","author":"Osorio","year":"2013","journal-title":"Hum Vaccines Immunother."},{"key":"ref_129","first-page":"5","article-title":"Superior Efficacy and Safety of a Nonemulsive Variant of the NGcGM3\/VSSP Vaccine in Advanced Breast Cancer Patients","volume":"10","author":"Vega","year":"2016","journal-title":"Breast Cancer"},{"key":"ref_130","first-page":"373","article-title":"Towards a network theory of the immune system","volume":"125C","author":"Jerne","year":"1974","journal-title":"Ann. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2000.18.2.376","article-title":"Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2","volume":"18","author":"Foon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3389\/fimmu.2019.00808","article-title":"The Promise of Anti-idiotype Revisited","volume":"10","author":"Kohler","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1089\/hyb.1998.17.527","article-title":"Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody","volume":"17","author":"Alfonso","year":"1998","journal-title":"Hybridoma"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00262-018-2188-y","article-title":"Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients","volume":"67","author":"Segatori","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.cji.0000188502.11348.34","article-title":"Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients","volume":"29","author":"Guthmann","year":"2006","journal-title":"J. Immunother."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"13072","DOI":"10.1038\/s41598-017-12231-8","article-title":"HLA and Histo-Blood Group Antigen Expression in Human Pluripotent Stem Cells and their Derivatives","volume":"7","author":"Barone","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_137","first-page":"295","article-title":"Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers","volume":"4","author":"Zhang","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-14-1651","article-title":"Globo-H ceramide shed from cancer cells triggers translin-associated factor X-dependent angiogenesis","volume":"74","author":"Cheng","year":"2014","journal-title":"Cancer Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1073\/pnas.96.10.5710","article-title":"Carbohydrate vaccines in cancer: Immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man","volume":"96","author":"Slovin","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.051626298","article-title":"Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial","volume":"98","author":"Gilewski","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1073\/pnas.1816946116","article-title":"Signaling pathway of globo-series glycosphingolipids and \u03b21,3-galactosyltransferase V (\u03b23GalT5) in breast cancer","volume":"116","author":"Chuang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/imcb.12314","article-title":"Exploiting the internalization feature of an antibody against the glycosphingolipid SSEA-4 to deliver immunotoxins in breast cancer cells","volume":"98","author":"Ruggiero","year":"2020","journal-title":"Immunol. Cell Biol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-20-0763","article-title":"Preclinical Studies of OBI-999: A Novel Globo H-Targeting Antibody-Drug Conjugate","volume":"20","author":"Yang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1042\/BCJ20180103","article-title":"O-glycan recognition and function in mice and human cancers","volume":"477","author":"Cervoni","year":"2020","journal-title":"Biochem. J."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/glycob\/cwr182","article-title":"Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family","volume":"22","author":"Bennett","year":"2012","journal-title":"Glycobiology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/(SICI)1097-0215(20000615)86:6<753::AID-IJC1>3.0.CO;2-#","article-title":"Tn antigen is a pre-cancerous biomarker in breast tissue and serum in n-nitrosomethylurea-induced rat mammary carcinogenesis","volume":"86","author":"Babino","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_147","first-page":"219","article-title":"Oncol Simple mucin-type cancer associated antigens are pre-cancerous biomarkers during 1,2-dimethylhydrazine-induced rat colon carcinogenesis","volume":"14","author":"Berriel","year":"2005","journal-title":"Oncol. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1084\/jem.20061929","article-title":"Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans","volume":"204","author":"An","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.bbagen.2016.03.008","article-title":"Short O-GalNAc glycans: Regulation and role in tumor development and clinical perspectives","volume":"1860","author":"Chia","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tan.12900","article-title":"Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen","volume":"88","author":"Fu","year":"2016","journal-title":"HLA"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Munkley, J. (2016). The Role of Sialyl-Tn in Cancer. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17030275"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/0008-5472.CAN-07-2345","article-title":"Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc","volume":"68","author":"Ju","year":"2008","journal-title":"Cancer Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"41523","DOI":"10.1074\/jbc.M112.371989","article-title":"Epigenetic silencing of the chaperone Cosmc in human leukocytes expressing Tn antigen","volume":"287","author":"Mi","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1083\/jcb.201003055","article-title":"Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes","volume":"189","author":"Gill","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"E3152","DOI":"10.1073\/pnas.1305269110","article-title":"Initiation of GalNAc-type O-glycosylation in the endoplasmic reticulum promotes cancer cell invasiveness","volume":"110","author":"Gill","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","first-page":"4361","article-title":"Immunoglobulin G3 monoclonal antibody directed to Tn antigen (tumor-associated alpha-N-acetylgalactosaminyl epitope) that does not cross-react with blood group A antigen","volume":"48","author":"Takahashi","year":"1988","journal-title":"Cancer Res."},{"key":"ref_157","first-page":"587","article-title":"Pancarcinoma T and Tn epitopes: Autoimmunogens and diagnostic markers that reveal incipient carcinomas and help establish prognosis","volume":"53","author":"Springer","year":"1990","journal-title":"Immunol. Ser."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0006-291X(90)90488-9","article-title":"A monoclonal antibody directed to Tn antigen","volume":"170","author":"Numata","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1537-2995.1991.31291142945.x","article-title":"Immunochemical studies on the differential binding properties of two monoclonal antibodies reacting with Tn red cells","volume":"31","author":"King","year":"1991","journal-title":"Transfusion"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0165-2478(93)90095-J","article-title":"Use of O-glycosylation-defective human lymphoid cell lines and flow cytometry to delineate the specificity of Moluccella laevis lectin and monoclonal antibody 5F4 for the Tn antigen (GalNAc alpha 1-O-Ser\/Thr)","volume":"36","author":"Thurnher","year":"1993","journal-title":"Immunol. Lett."},{"key":"ref_161","first-page":"2229","article-title":"Expression of Tn and sialyl-Tn antigens in the neoplastic transformation of uterine cervical epithelial cells","volume":"56","author":"Terasawa","year":"1996","journal-title":"Cancer Res."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1006939432665","article-title":"Development and characterization of an antibody directed to an alpha-N-acetyl-D-galactosamine glycosylated MUC2 peptide","volume":"15","author":"Reis","year":"1998","journal-title":"Glycoconj. J."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0014-5793(00)01248-5","article-title":"Analysis of the fine specificity of Tn-binding proteins using synthetic glycopeptide epitopes and a biosensor based on surface plasmon resonance spectroscopy","volume":"469","author":"Osinaga","year":"2000","journal-title":"FEBS Lett."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1046\/j.1432-1033.2002.02787.x","article-title":"NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3","volume":"269","author":"Serttas","year":"2002","journal-title":"Eur. J. Biochem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1126\/science.1129200","article-title":"A mutant chaperone converts a wild-type protein into a tumor-specific antigen","volume":"314","author":"Schietinger","year":"2006","journal-title":"Science"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00262-006-0135-9","article-title":"PankoMab: A potent new generation anti-tumour MUC1 antibody","volume":"55","author":"Danielczyk","year":"2006","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/glycob\/cwl061","article-title":"Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat","volume":"17","author":"Tarp","year":"2007","journal-title":"Glycobiology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1248\/bpb.31.1739","article-title":"Mouse-human chimeric anti-Tn IgG1 induced anti-tumor activity against Jurkat cells in vitro and in vivo","volume":"31","author":"Ando","year":"2008","journal-title":"Biol. Pharm. Bull."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/glycob\/cwp085","article-title":"A newly generated functional antibody identifies Tn antigen as a novel determinant in the cancer cell-lymphatic endothelium interaction","volume":"19","author":"Danussi","year":"2009","journal-title":"Glycobiology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/glycob\/cwr048","article-title":"A new murine IgG1 anti-Tn monoclonal antibody with in vivo anti-tumor activity","volume":"21","author":"Welinder","year":"2011","journal-title":"Glycobiology"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00262-018-2206-0","article-title":"Production of a mouse monoclonal IgM antibody that targets the carbohydrate Thomsen-nouveau cancer antigen resulting in in vivo and in vitro tumor killing","volume":"67","author":"Trabbic","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/glycob\/cwz004","article-title":"A strategy for generating cancer-specific monoclonal antibodies to aberrant O-glycoproteins: Identification of a novel dysadherin-Tn antibody","volume":"29","author":"Steentoft","year":"2019","journal-title":"Glycobiology"},{"key":"ref_173","first-page":"282","article-title":"Identification of Tn antigen O-GalNAc-expressing glycoproteins in human carcinomas using novel anti-Tn recombinant antibodies","volume":"30","author":"Matsumoto","year":"2020","journal-title":"Glycobiology"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1016\/S0021-9258(18)69074-X","article-title":"The oncofetal structure of human fibronectin defined by monoclonal antibody FDC-6. Unique structural requirement for the antigenic specificity provided by a glycosylhexapeptide","volume":"263","author":"Matsuura","year":"1988","journal-title":"J. Biol. Chem."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"9946","DOI":"10.1021\/bi012176z","article-title":"Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions","volume":"41","author":"Grinstead","year":"2002","journal-title":"Biochemistry"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"e001128","DOI":"10.1136\/jitc-2020-001128","article-title":"PODO447: A novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin","volume":"8","author":"Hughes","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1046\/j.1432-1327.2000.01141.x","article-title":"Biochemical and functional characterization of the Tn-specific lectin from Salvia sclarea seeds","volume":"267","author":"Medeiros","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1073\/pnas.90.6.2495","article-title":"Epitopic structure of Tn glycophorin A for an anti-Tn antibody (MLS 128)","volume":"90","author":"Nakada","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00262-013-1425-7","article-title":"Monoclonal antibodies toward different Tn-amino acid backbones display distinct recognition patterns on human cancer cells. Implications for effective immuno-targeting of cancer","volume":"62","author":"Mazal","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/cbic.200500165","article-title":"Carbohydrate array analysis of anti-Tn antibodies and lectins reveals unexpected specificities: Implications for diagnostic and vaccine development","volume":"6","author":"Manimala","year":"2005","journal-title":"ChemBioChem"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/glycob\/cwr178","article-title":"Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells","volume":"22","author":"Blixt","year":"2012","journal-title":"Glycobiology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10719-012-9437-7","article-title":"Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity","volume":"30","author":"Lavrsen","year":"2013","journal-title":"Glycoconj. J."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Gong, Y., Klein Wolterink, R.G.J., Gulaia, V., Cloosen, S., Ehlers, F.A.I., Wieten, L., Graus, Y.F., Bos, G.M.J., and Germeraad, W.T.V. (2021). Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity. Cancers, 13.","DOI":"10.3390\/cancers13112579"},{"key":"ref_184","first-page":"32","article-title":"Inhibition of cancer cell growth by anti-Tn monoclonal antibody MLS128","volume":"3","author":"Morita","year":"2009","journal-title":"Biosci. Trends."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1","article-title":"Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides","volume":"86","author":"Petrakou","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/02724570050109620","article-title":"Production and functional characterization of two mouse\/human chimeric antibodies with specificity for the tumor-associated Tn-antigen","volume":"19","author":"Oppezzo","year":"2000","journal-title":"Hybridoma"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/hyb.1990.9.389","article-title":"Production of a monoclonal antibody as immunohistochemical marker on paraffin embedded tissues using a new immunization method","volume":"9","author":"Pancino","year":"1990","journal-title":"Hybridoma"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e1171434","DOI":"10.1080\/2162402X.2016.1171434","article-title":"Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen","volume":"5","author":"Sedlik","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ijbiomac.2021.04.054","article-title":"Docetaxel in chitosan-based nanocapsules conjugated with an anti-Tn antigen mouse\/human chimeric antibody as a promising targeting strategy of lung tumors","volume":"182","author":"Castro","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s001090050144","article-title":"Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy","volume":"75","author":"Springer","year":"1997","journal-title":"J. Mol. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2003.04.112","article-title":"Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: Clinical trial results with alpha-N-acetylgalactosamine-O-serine\/threonine conjugate vaccine","volume":"21","author":"Slovin","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1021\/ja9825128","article-title":"Synthetic and immunological studies of clustered modes of mucin-related Tn and TF O-linked antigens: The preparation of a glycopeptide-based vaccines for clinical trials against prostate cancer","volume":"120","author":"Kuduk","year":"1998","journal-title":"J. Am. Chem. Soc."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.4049\/jimmunol.166.4.2849","article-title":"Anti-tumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope","volume":"166","author":"Bay","year":"2001","journal-title":"J. Immunol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00262-016-1802-0","article-title":"The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity","volume":"65","author":"Laubreton","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00262-006-0274-z","article-title":"The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma","volume":"56","author":"Saeland","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.canlet.2021.06.012","article-title":"The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2)","volume":"518","author":"Carasi","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3389\/fonc.2020.01622","article-title":"Tn Antigen Expression Contributes to an Immune Suppressive Microenvironment and Drives Tumor Growth in Colorectal Cancer","volume":"10","author":"Cornelissen","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.canlet.2006.08.010","article-title":"Biological significance of cancer-associated sialyl-Tn antigen: Modulation of malignant phenotype in gastric carcinoma cells","volume":"249","author":"Pinho","year":"2007","journal-title":"Cancer Lett."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/glycob\/cwj033","article-title":"ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity","volume":"16","author":"Julien","year":"2006","journal-title":"Glycobiology"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10585-011-9445-1","article-title":"Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model","volume":"29","author":"Ozaki","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.molonc.2014.02.008","article-title":"Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells","volume":"8","author":"Carrascal","year":"2014","journal-title":"Mol. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1073\/pnas.78.5.3199","article-title":"A spectrum of monoclonal antibodies reactive with human mammary tumor cells","volume":"78","author":"Colcher","year":"1981","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_203","first-page":"850","article-title":"Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3","volume":"46","author":"Johnson","year":"1986","journal-title":"Cancer Res."},{"key":"ref_204","first-page":"4588","article-title":"Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen","volume":"48","author":"Muraro","year":"1988","journal-title":"Cancer Res."},{"key":"ref_205","first-page":"2214","article-title":"Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2\u20146 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope","volume":"48","author":"Kjeldsen","year":"1988","journal-title":"Cancer Res."},{"key":"ref_206","first-page":"3364","article-title":"Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen","volume":"55","author":"Zhang","year":"1995","journal-title":"Cancer Res."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1006935331756","article-title":"; Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa","volume":"15","author":"Ogata","year":"1998","journal-title":"Glycoconj. J."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1018576224062","article-title":"Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes","volume":"14","author":"Reddish","year":"1997","journal-title":"Glycoconj. J."},{"key":"ref_209","first-page":"4597","article-title":"Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies","volume":"48","author":"Colcher","year":"1988","journal-title":"Cancer Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hyb.1995.14.461","article-title":"Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49","volume":"14","author":"Kashmiri","year":"1995","journal-title":"Hybridoma"},{"key":"ref_211","first-page":"1491","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49","volume":"37","author":"Meredith","year":"1996","journal-title":"J. Nucl. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1006\/gyno.1996.4577","article-title":"Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: A phase I\/II study","volume":"65","author":"Alvarez","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"ref_213","first-page":"305","article-title":"Intraperitoneal radioimmunochemotherapy of ovarian cancer: A phase I study","volume":"16","author":"Meredith","year":"2001","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_214","first-page":"3254s","article-title":"Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer","volume":"5","author":"Meredith","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"ref_215","first-page":"502","article-title":"Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region","volume":"20","author":"Rogers","year":"2005","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2967\/jnumed.120.243394","article-title":"TAG-72-Targeted alpha-Radionuclide Therapy of Ovarian Cancer Using (225)Ac-Labeled DOTAylated-huCC49 Antibody","volume":"62","author":"Minnix","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/cgt.2008.11","article-title":"Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes","volume":"15","author":"Kim","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1002\/cam4.3078","article-title":"Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer","volume":"9","author":"Minnix","year":"2020","journal-title":"Cancer Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/19420862.2017.1290752","article-title":"Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity","volume":"9","author":"Prendergast","year":"2017","journal-title":"MAbs"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002620050542","article-title":"Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells","volume":"48","author":"Ragupathi","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1038\/sj.bjc.6605083","article-title":"Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model","volume":"100","author":"Julien","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1586\/14760584.3.6.655","article-title":"Vaccination with Theratope (STn-KLH) as treatment for breast cancer","volume":"3","author":"Holmberg","year":"2004","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/biom2040435","article-title":"Sialyl-tn in cancer: (how) did we miss the target?","volume":"2","author":"Julien","year":"2012","journal-title":"Biomolecules."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3389\/fonc.2016.00079","article-title":"Interaction of the Oncofetal Thomsen-Friedenreich Antigen with Galectins in Cancer Progression and Metastasis","volume":"6","author":"Sindrewicz","year":"2016","journal-title":"Front. Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1134\/S0006297915070019","article-title":"What controls the expression of the core-1 (Thomsen-Friedenreich) glycotope on tumor cells?","volume":"80","author":"Karsten","year":"2015","journal-title":"Biochemistry (Mosc)."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/glycob\/cwr058","article-title":"Occurrence of the human tumor-specific antigen structure Gal\u03b21-3GalNAc\u03b1- (Thomsen-Friedenreich) and related structures on gut bacteria: Prevalence, immunochemical analysis and structural confirmation","volume":"21","author":"Henderson","year":"2011","journal-title":"Glycobiology"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"830847","DOI":"10.1155\/2014\/830847","article-title":"Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: A diagnostic and prognostic potential","volume":"2014","author":"Kurtenkov","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"48","DOI":"10.31768\/2312-8852.2018.40(1):48-58","article-title":"Signatures of anti-Thomsen\u2014Friedenreich antigen antibody diversity in colon cancer patients","volume":"40","author":"Kurtenkov","year":"2018","journal-title":"Exp Oncol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"9747040","DOI":"10.1155\/2020\/9747040","article-title":"Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential","volume":"2020","author":"Kurtenkov","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"ref_230","first-page":"263","article-title":"The Thomsen-Friedenreich (TF) antigen: A critical review on the structural, biosynthetic and histochemical aspects of a pancarcinoma-associated antigen","volume":"12","author":"Hanisch","year":"1997","journal-title":"Histol. Histopathol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/hyb.1998.17.165","article-title":"Development and characterization of monoclonal antibody to T-antigen: (gal beta1-3GalNAc-alpha-O)","volume":"17","author":"Xia","year":"1998","journal-title":"Hybridoma"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1593\/neo.06493","article-title":"Inhibition of spontaneous breast cancer metastasis by anti-Thomsen-Friedenreich antigen monoclonal antibody JAA-F11","volume":"8","author":"Heimburg","year":"2006","journal-title":"Neoplasia"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1517\/14712598.7.7.923","article-title":"Jaa-f11: Extending the life of mice with breast cancer","volume":"7","year":"2007","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2217\/fon.13.209","article-title":"Preclinical studies with JAA-F11 anti-Thomsen-Friedenreich monoclonal antibody for human breast cancer","volume":"10","author":"Ferguson","year":"2014","journal-title":"Future Oncol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.neo.2017.07.001","article-title":"Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis","volume":"19","author":"Tati","year":"2017","journal-title":"Neoplasia"},{"key":"ref_236","first-page":"489","article-title":"Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers","volume":"78","author":"Longenecker","year":"1987","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1158\/1078-0432.CCR-05-0211","article-title":"High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111\/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody","volume":"11","author":"Richman","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1021\/acs.bioconjchem.0c00282","article-title":"A Peptide-Duocarmycin Conjugate Targeting the Thomsen-Friedenreich Antigen Has Potent and Selective Antitumor Activity","volume":"31","author":"Cartwright","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/15216540601188553","article-title":"Expression of cancer-associated simple mucin-type O-glycosylated antigens in parasites","volume":"59","author":"Osinaga","year":"2007","journal-title":"IUBMB Life"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1006\/expr.2001.4620","article-title":"O-glycosylation in Echinococcus granulosus: Identification and characterization of the carcinoma-associated Tn antigen","volume":"98","author":"Medeiros","year":"2001","journal-title":"Exp. Parasitol."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0020-7519(02)00231-X","article-title":"Mucin type O-glycosylation in Fasciola hepatica: Characterization of carcinoma associated Tn and sialyl-Tn antigens and evaluation of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase activity","volume":"33","author":"Freire","year":"2003","journal-title":"Int. J. Parasitol."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1645\/GE-2970","article-title":"Mucin-Type O-Glycosylation in helminth parasites from major taxonomic groups: Evidence for widespread distribution of the Tn Antigen (GalNAc-Ser\/Thr) and identification of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase activity","volume":"89","author":"Casaravilla","year":"2003","journal-title":"J. Parasitol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ijpara.2007.07.015","article-title":"Mucin-type O-glycosylation in Mesocestoides vogae (syn. corti)","volume":"38","author":"Medeiros","year":"2008","journal-title":"Int. J. Parasitol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.bbrc.2003.11.060","article-title":"Sialyl-Tn antigen expression and O-linked GalNAc-Thr synthesis by Trypanosoma cruzi","volume":"312","author":"Freire","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1016\/j.semcancer.2015.03.004","article-title":"Immune evasion in cancer: Mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"775","DOI":"10.3892\/ijo.2013.2000","article-title":"Mucin-like peptides from Echinococcus granulosus induce antitumor activity","volume":"43","author":"Noya","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"230176","DOI":"10.1155\/2013\/230176","article-title":"Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer","volume":"2013","author":"Berriel","year":"2013","journal-title":"Sci. World J."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/ijc.29910","article-title":"Trypanosoma cruzi extracts elicit protective immune response against chemically induced colon and mammary cancers","volume":"138","author":"Ubillos","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1007\/s00262-021-02948-x","article-title":"Human hydatid cyst fluid-induced therapeutic anti-cancer immune responses via NK1.1+ cell activation in mice","volume":"70","author":"Berriel","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fonc.2018.00039","article-title":"Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy","volume":"8","author":"Blanas","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1016\/j.bbagen.2015.12.026","article-title":"Histo-blood group glycans in the context of personalized medicine","volume":"1860","author":"Dotz","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/1354750X.2021.1876770","article-title":"Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: Meta-analysis and systematic review of literature","volume":"26","author":"Skulimowski","year":"2021","journal-title":"Biomarkers"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"4903","DOI":"10.7150\/thno.42480","article-title":"Esophageal, gastric and colorectal cancers: Looking beyond classical serological biomarkers towards glycoproteomics-assisted precision oncology","volume":"10","author":"Fernandes","year":"2020","journal-title":"Theranostics"},{"key":"ref_254","first-page":"1033","article-title":"Carcinoembryonic antigen is a sialyl Lewis x\/a carrier and an E-selectin ligand in non-small cell lung cancer","volume":"55","author":"Ferreira","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/1078-0432.CCR-10-2640","article-title":"Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity","volume":"17","author":"Sawada","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"e16235","DOI":"10.1200\/JCO.2018.36.15_suppl.e16235","article-title":"HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem\/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies","volume":"36","author":"Borazanci","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"O'Reilly, E.A., Lohrmann, C., O'Donoghue, J.A., Borazanci, E., Estrella, H., Teng, R., Melink, T., Dorr, K., Kearns, C., and Peterson, M. (2018, January 14\u201318). Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed \/ refractory pancreatic cancer or other CA19-9+ malignancies. Proceedings of the American Association for Cancer Research Annual Meeting 2018, Chicago, IL, USA.","DOI":"10.1158\/1538-7445.AM2018-CT140"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/1535-7163.MCT-19-0221","article-title":"Monoclonal Antibody Targeting Sialyl-di-Lewisa-Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential","volume":"19","author":"Tivadar","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"12957","DOI":"10.1073\/pnas.91.26.12957","article-title":"Specificity analysis of blood group Lewis-y (Le(y)) antibodies generatedagainst synthetic and natural Le(y) determinants","volume":"91","author":"Kitamura","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_260","first-page":"3254","article-title":"Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors","volume":"60","author":"Scott","year":"2000","journal-title":"Cancer Res."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/ijgc-2020-002239","article-title":". Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission","volume":"31","author":"Smaletz","year":"2021","journal-title":"Int. J. Gynecol. Cancer."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_263","doi-asserted-by":"crossref","unstructured":"Chen, J., Pan, Z., Han, L., Zhou, Y., Zong, H., Wang, L., Sun, R., Jiang, H., Xie, Y., and Yuan, Y. (2021). A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer. Biomedicines, 9.","DOI":"10.3390\/biomedicines9081059"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0022-2836(05)80044-0","article-title":"Crystallization and preliminary X-ray analysis of the monoclonal anti-tumor antibody BR96 and its complex with the Lewis Y determinant","volume":"235","author":"Chang","year":"1994","journal-title":"J. Mol. Biol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1200\/JCO.1999.17.2.478","article-title":"Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer","volume":"17","author":"Tolcher","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s00262-008-0654-7","article-title":"Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine","volume":"58","author":"Ragupathi","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10719-020-09912-4","article-title":"The physiological and pathological roles and applications of sialyl Lewis x, a common carbohydrate ligand of the three selectins","volume":"37","author":"Jin","year":"2020","journal-title":"Glycoconj. J."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0092-8674(94)90337-9","article-title":"Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm","volume":"76","author":"Springer","year":"1994","journal-title":"Cell"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cyto.2015.04.006","article-title":"Inflammatory cytokines regulate the expression of glycosyltransferases involved in the biosynthesis of tumor-associated sialylated glycans in pancreatic cancer cell lines","volume":"75","author":"Allende","year":"2015","journal-title":"Cytokine"},{"key":"ref_270","first-page":"354","article-title":"Contribution of carbohydrate antigens Sialyl Lewis A and Sialyl Lewis X to adhesion of human cancer cells to vascular endothelium","volume":"53","author":"Takada","year":"1993","journal-title":"Cancer Res."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1098-2744(200004)27:4<280::AID-MC6>3.0.CO;2-L","article-title":"Transfection of alpha(1,3)fucosyltransferase antisense sequences impairs the proliferative and tumorigenic ability of human colon carcinoma cells","volume":"27","author":"Hiller","year":"2000","journal-title":"Mol. Carcinog."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"10511","DOI":"10.1016\/S0021-9258(18)90993-2","article-title":"Novel fucolipids accumulating in human adenocarcinoma. III. A hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside (VI3NeuAcV3III3Fuc2nLc6)","volume":"259","author":"Fukushi","year":"1984","journal-title":"J. Biol. Chem."},{"key":"ref_273","first-page":"5279","article-title":"Characterization of sialosylated Lewisx as a new tumor-associated antigen","volume":"44","author":"Fukushima","year":"1984","journal-title":"Cancer Res."},{"key":"ref_274","first-page":"3138","article-title":"Sialyl Lewis(x) antigen as defined by monoclonal antibody AM-3 is a marker of dysplasia in the colonic adenoma-carcinoma sequence","volume":"52","author":"Hanisch","year":"1992","journal-title":"Cancer Res."},{"key":"ref_275","unstructured":"(1993). Dohi T, Nemoto T, Ohta S, Shitara K, Hanai N, Nudelman E, Hakomori S, Oshima M Different binding properties of three monoclonal antibodies to sialyl Le(x) glycolipids in a gastric cancer cell line and normal stomach tissue. Anticancer Res., 13, 1277\u20131282."},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.abb.2004.04.008","article-title":"The discovery, biology, and drug development of sialyl Lea and sialyl Lex","volume":"426","author":"Magnani","year":"2004","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_277","first-page":"3113","article-title":"Clinicopathological and prognostic significance of sialyl Lewis X overexpression in patients with cancer: A meta-analysis","volume":"9","author":"Liang","year":"2016","journal-title":"Onco-Targets Ther."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1373\/clinchem.2016.260968","article-title":"Sandwich ELISA Using a Mouse\/Human Chimeric CSLEX-1 Antibody","volume":"62","author":"Yamashita","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/00000658-199210000-00010","article-title":"Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine","volume":"216","author":"Morton","year":"1992","journal-title":"Ann. Surg."},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1097-0215(19980105)75:1<117::AID-IJC18>3.0.CO;2-D","article-title":"Ratio of IgG:IgM antibodies to sialyl Lewis(x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice","volume":"75","author":"Ravindranath","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/10870","article-title":"Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses","volume":"17","author":"Luo","year":"1999","journal-title":"Nat. Biotechnol."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3109\/1061186X.2013.862805","article-title":"Targeting liposomes loaded with melphalan prodrug to tumour vasculature via the Sialyl Lewis X selectin ligand","volume":"22","author":"Kuznetsova","year":"2014","journal-title":"J. Drug Target."},{"key":"ref_283","first-page":"6055","article-title":"Cisplatin-loaded, Sialyl Lewis X-Modified Liposomes: Drug Release, Biodistribution and Antitumor Efficacy","volume":"37","author":"Kishimoto","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bjc.6600048","article-title":"Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells","volume":"86","author":"Matsumoto","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_285","first-page":"3978","article-title":"Cimetidine inhibits cancer cell adhesion to endothelial cells and prevents metastasis by blocking E-selectin expression","volume":"60","author":"Kobayashi","year":"2000","journal-title":"Cancer Res."},{"key":"ref_286","first-page":"537","article-title":"Cimetidine inhibits the adhesion of gastric cancer cells expressing high levels of sialyl Lewis x in human vascular endothelial cells by blocking E-selectin expression","volume":"27","author":"Liu","year":"2011","journal-title":"Int. J. Mol. Med."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s00280-016-3006-x","article-title":"Inhibition of E-selectin expression on the surface of endothelial cells inhibits hepatocellular carcinoma growth by preventing tumor angiogenesis","volume":"77","author":"Borentain","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.accb.2018.09.001","article-title":"Exploration of the Sialic Acid World","volume":"75","author":"Schauer","year":"2018","journal-title":"Adv. Carbohydr. Chem. Biochem."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"108376","DOI":"10.1016\/j.carres.2021.108376","article-title":"The polyfunctional polysialic acid: A structural view","volume":"507","author":"Mindler","year":"2021","journal-title":"Carbohydr. Res."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1074\/jbc.RA117.000401","article-title":"Autopolysialylation of polysialyltransferases is required for polysialylation and polysialic acid chain elongation on select glycoprotein substrates","volume":"293","author":"Bhide","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_291","first-page":"114","article-title":"Glycobiology of neuroblastoma: Impact on tumor behavior, prognosis, and therapeutic strategies","volume":"4","author":"Berois","year":"2014","journal-title":"Front. Oncol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3892\/ijmm.2015.2395","article-title":"Enhanced expression of polysialic acid correlates with malignant phenotype in breast cancer cell lines and clinical tissue samples","volume":"37","author":"Wang","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lfs.2017.02.002","article-title":"Expression of polysialic acid in primary laryngeal squamous cell carcinoma","volume":"173","author":"Visentin","year":"2017","journal-title":"Life Sci."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1053\/j.gastro.2008.02.023","article-title":"Polysialylated NCAM represses E-cadherin-mediated cell-cell adhesion in pancreatic tumor cells","volume":"134","author":"Schreiber","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_295","first-page":"3072","article-title":"Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer","volume":"60","author":"Tanaka","year":"2000","journal-title":"Cancer Res."},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3892\/or.2016.5279","article-title":"Effects of the regulation of polysialyltransferase ST8SiaII on the invasiveness and metastasis of small cell lung cancer cells","volume":"37","author":"Gong","year":"2017","journal-title":"Oncol. Rep."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"100892","DOI":"10.1016\/j.mam.2020.100892","article-title":"Polysialylation and disease","volume":"79","author":"Sato","year":"2021","journal-title":"Mol. Aspects Med."},{"key":"ref_298","doi-asserted-by":"crossref","unstructured":"Jarahian, M., Marofi, F., Maashi, M.S., Ghaebi, M., Khezri, A., and Berger, M.R. (2021). Re-Expression of Poly\/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape. Cancers, 13.","DOI":"10.3390\/cancers13205203"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0022-1759(02)00298-3","article-title":"The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat","volume":"270","author":"Takeuchi","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/glycob\/6.3.289","article-title":"Unique alpha 2, 8-polysialylated glycoproteins in breast cancer and leukemia cells","volume":"6","author":"Martersteck","year":"1996","journal-title":"Glycobiology"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1515\/bchm3.1993.374.7-12.993","article-title":"Primary structure of the murine monoclonal IgG2a antibody mAb735 against alpha (2-8) polysialic acid. 2. Amino acid sequence of the heavy (H-) chain Fd' region","volume":"374","author":"Klebert","year":"1993","journal-title":"Biol. Chem. Hoppe Seyler"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/0008-5472.CAN-18-3119","article-title":"Antibody-Mediated Endocytosis of Polysialic Acid Enables Intracellular Delivery and Cytotoxicity of a Glycan-Directed Antibody-Drug Conjugate","volume":"79","author":"Cox","year":"2019","journal-title":"Cancer Res."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"13699","DOI":"10.1073\/pnas.202427599","article-title":"On the power of chemical synthesis: Immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines","volume":"99","author":"Ragupathi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1007\/s00262-007-0335-y","article-title":"A polyvalent vaccine for high-risk prostate patients: \"are more antigens better?\"","volume":"56","author":"Slovin","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1158\/1078-0432.CCR-06-2949","article-title":"Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"13","author":"Sabbatini","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1021\/ja057244+","article-title":"Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: A synthetic route to anticancer vaccine candidates","volume":"128","author":"Ragupathi","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: Continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"1777064","DOI":"10.1080\/2162402X.2020.1777064","article-title":"Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors","volume":"9","author":"Alcantara","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ijc.1457","article-title":"Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes","volume":"94","author":"Rossig","year":"2001","journal-title":"Int. J. Cancer"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Nat Virus-specific T cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"eabd6169","DOI":"10.1126\/scitranslmed.abd6169","article-title":"Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma","volume":"12","author":"Straathof","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_314","doi-asserted-by":"crossref","unstructured":"Yu, L., Huang, L., Lin, D., Lai, X., Wu, L., Liao, X., Liu, J., Zeng, Y., Liang, L., and Zhang, G. (2021). GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and\/or recurrent neuroblastoma in pediatric patients. J. Cancer Res. Clin. Oncol.","DOI":"10.21203\/rs.3.rs-803629\/v1"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13045-021-01193-0","article-title":"Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma","volume":"14","author":"Tumino","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: An interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-08-3163","article-title":"Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells","volume":"15","author":"Yvon","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","article-title":"Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients","volume":"11","author":"Yu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_320","doi-asserted-by":"crossref","unstructured":"Soltantoyeh, T., Akbari, B., Karimi, A., Mahmoodi, C.G., Ghahri-Saremi, N., Hadjati, J., Hamblin, M.R., and Mirzaei, H.R. (2021). Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells, 10.","DOI":"10.3390\/cells10061450"},{"key":"ref_321","first-page":"xi12","article-title":"Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer","volume":"30","author":"Lin","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"CT232","DOI":"10.1158\/1538-7445.AM2020-CT232","article-title":"Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*)","volume":"80","author":"Specht","year":"2020","journal-title":"Cancer Res."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.4049\/jimmunol.180.7.4901","article-title":"Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor","volume":"180","author":"Wilkie","year":"2008","journal-title":"J. Immunol."},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","article-title":"Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma","volume":"44","author":"Posey","year":"2016","journal-title":"Immunity"},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"e1284722","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11427-016-5024-7","article-title":"Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells","volume":"59","author":"You","year":"2016","journal-title":"Sci. China Life Sci."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.2733","article-title":"MUC1 as a target for CAR-T therapy in head and neck squamous cell carinoma","volume":"9","author":"Mei","year":"2020","journal-title":"Cancer Med."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"e003237","DOI":"10.1136\/jitc-2021-003237","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_329","first-page":"79","article-title":"MUC1-Tn-targeting chimeric antigen receptor-modified V\u03b39V\u03b42 T cells with enhanced antigen-specific anti-tumor activity","volume":"11","author":"Zhai","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"e14513","DOI":"10.1200\/JCO.2021.39.15_suppl.e14513","article-title":"Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors","volume":"15","author":"Gutierrez","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1053\/gast.1997.v113.pm9322511","article-title":"T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope","volume":"113","author":"Hombach","year":"1997","journal-title":"Gastroenterology"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1089\/10430349950018968","article-title":"Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor","volume":"10","author":"McGuinness","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ymthe.2019.06.007","article-title":"Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors","volume":"27","author":"Hombach","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective Targeting of TAG72 + Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol Ther Oncolytics."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1021\/acschembio.6b00084","article-title":"Recent Advance in Tumor-associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines","volume":"11","author":"Feng","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1039\/D0SC00544D","article-title":"Chemical synthesis and immunological evaluation of new generation multivalent anticancer vaccines based on a Tn antigen analogue","volume":"11","author":"Pifferi","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s10719-019-09884-0","article-title":"Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response","volume":"36","author":"Song","year":"2019","journal-title":"Glycoconj. J."},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1039\/D1OB00007A","article-title":"Synthesis and immunological evaluation of the unnatural beta-linked mucin-1 Thomsen-Friedenreich conjugate","volume":"19","author":"Wu","year":"2021","journal-title":"Org. Biomol. Chem."},{"key":"ref_341","doi-asserted-by":"crossref","unstructured":"Amon, R., Rosenfeld, R., Perlmutter, S., Grant, O.C., Yehuda, S., Borenstein-Katz, A., Alcalay, R., Marshanski, T., Yu, H., and Diskin, R. (2020). Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in Cancer. Cancers, 12.","DOI":"10.3390\/cancers12102824"},{"key":"ref_342","doi-asserted-by":"crossref","unstructured":"Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., and Anzaghe, M. (2021). The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22168947"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1158\/0008-5472.CAN-19-3599","article-title":"Engineering the Human Fc Region Enables Direct Cell Killing by Cancer Glycan-Targeting Antibodies without the Need for Immune Effector Cells or Complement","volume":"80","author":"Vankemmelbeke","year":"2020","journal-title":"Cancer Res."},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat. Chem. Biol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/645\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:09:10Z","timestamp":1760134150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":345,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030645"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030645","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]}}}